{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T07:01:57Z","timestamp":1794294117523,"version":"4.9.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.rmed.2026.108647","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T17:00:57Z","timestamp":1768237257000},"page":"108647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Fractional exhaled nitric oxide in monitoring biological treatment for severe asthma in adults: Clinical implications and future perspectives"],"prefix":"10.1016","volume":"252","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-9921","authenticated-orcid":false,"given":"Mauro","family":"Maniscalco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Candia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Ambrosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.rmed.2026.108647_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2026.108647_bib3","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jaip.2024.01.023","article-title":"Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics","volume":"12","author":"Bourdin","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.rmed.2026.108647_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10379","key":"10.1016\/j.rmed.2026.108647_bib5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","article-title":"Asthma","volume":"401","author":"Porsbjerg","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.rmed.2026.108647_bib6","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/1744666X.2025.2525443","article-title":"Biologics for severe asthma: deciphering what is best for the patient","volume":"21","author":"Cazzola","year":"2025","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"10516","key":"10.1016\/j.rmed.2026.108647_bib7","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/S0140-6736(25)01625-3","article-title":"Anti-cytokine biologics for asthma in adults","volume":"406","author":"Israel","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2026.108647_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13223-017-0219-4","article-title":"Asthma biomarkers in the age of biologics","volume":"13","author":"Kim","year":"2017","journal-title":"Allergy Asthma Clin. Immunol."},{"issue":"10","key":"10.1016\/j.rmed.2026.108647_bib9","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1164\/rccm.202109-2093ST","article-title":"Use of fractional exhaled nitric oxide to guide the treatment of asthma: an official American Thoracic Society clinical practice guideline","volume":"204","author":"Khatri","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2026.108647_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01633-2019","article-title":"Clinical utility of fractional exhaled nitric oxide in severe asthma management","volume":"55","author":"Menzies-Gow","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2026.108647_bib11","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.chest.2021.10.015","article-title":"Using fractional exhaled nitric oxide measurement in clinical asthma management","volume":"161","author":"Rupani","year":"2022","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2026.108647_bib12","first-page":"36","article-title":"Fractional exhaled nitric oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP\/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC)","volume":"15","author":"Heffler","year":"2020","journal-title":"Multidiscip Respir Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.108647_bib13","first-page":"1006","article-title":"The role of fractional exhaled nitric oxide (FeNO) in asthma management: an Italian consensus statement on clinical and economic aspects","volume":"20","author":"Bonini","year":"2025","journal-title":"Multidiscip Respir Med."},{"issue":"4","key":"10.1016\/j.rmed.2026.108647_bib14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.freeradbiomed.2006.05.011","article-title":"Nitric oxide and reactive nitrogen species in airway epithelial signaling and inflammation","volume":"41","author":"Bove","year":"2006","journal-title":"Free Radic. Biol. Med."},{"issue":"7","key":"10.1016\/j.rmed.2026.108647_bib15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","article-title":"Nitric oxide synthases: regulation and function","volume":"33","author":"F\u00f6rstermann","year":"2012","journal-title":"Eur. Heart J."},{"issue":"Suppl 5","key":"10.1016\/j.rmed.2026.108647_bib16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1289\/ehp.98106s51119","article-title":"Characterization of inducible nitric oxide synthase expression in human airway epithelium","volume":"106","author":"Guo","year":"1998","journal-title":"Environ. Health Perspect."},{"issue":"1","key":"10.1016\/j.rmed.2026.108647_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/ACI.0000000000000877","article-title":"Exhaled nitric oxide in asthma: from diagnosis to management","volume":"23","author":"Guida","year":"2023","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"42","key":"10.1016\/j.rmed.2026.108647_bib18","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.2174\/0929867327666200713184659","article-title":"An emerging role for exhaled nitric oxide in guiding biological treatment in severe asthma","volume":"27","author":"Rolla","year":"2020","journal-title":"Curr. Med. Chem."},{"issue":"5","key":"10.1016\/j.rmed.2026.108647_bib19","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108647_bib20","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front. Physiol."},{"issue":"2","key":"10.1016\/j.rmed.2026.108647_bib21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1183\/09031936.00089008","article-title":"Reciprocal regulation of iNOS and PARP-1 during allergen-induced eosinophilia","volume":"33","author":"Naura","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"2 Pt 2","key":"10.1016\/j.rmed.2026.108647_bib22","doi-asserted-by":"crossref","first-page":"S547","DOI":"10.1016\/S0091-6749(00)90059-9","article-title":"Molecular mechanisms of IgE regulation","volume":"105","author":"Bacharier","year":"2000","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.rmed.2026.108647_bib23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jaci.2016.04.056","article-title":"Half-life of IgE in serum and skin: consequences for anti-IgE therapy in patients with allergic disease","volume":"139","author":"Lawrence","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2026.108647_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1055\/s-0037-1606217","article-title":"Airway inflammation and inflammatory biomarkers","volume":"39","author":"Lim","year":"2018","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2026.108647_bib25","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jaci.2021.11.021","article-title":"Considering biomarkers in asthma disease severity","volume":"149","author":"Custovic","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"10.1016\/j.rmed.2026.108647_bib26","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"22","key":"10.1016\/j.rmed.2026.108647_bib27","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1001\/jama.2020.21974","article-title":"Managing asthma in adolescents and adults: 2020 asthma guideline update from the National Asthma Education and Prevention Program","volume":"324","author":"Cloutier","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.rmed.2026.108647_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.r1162","article-title":"Asthma: diagnosis, monitoring, and chronic asthma management: summary of guidance from BTS\/NICE\/SIGN","volume":"390","author":"Fowler","year":"2025","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.rmed.2026.108647_bib34","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00370-2023","article-title":"ERS technical standard: Global Lung Function Initiative reference values for exhaled nitric oxide fraction (FENO50)","volume":"63","author":"H\u00f6gman","year":"2024","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2026.108647_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1378\/chest.12-0416","article-title":"Normal values and thresholds for the clinical interpretation of exhaled nitric oxide levels in the US general population: results from the National Health and Nutrition Examination Survey 2007-2010","volume":"143","author":"See","year":"2013","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.rmed.2026.108647_bib36","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1152\/japplphysiol.00093.2018","article-title":"Exhaled NO reference limits in a large population-based sample using the lambda-mu-sigma method","volume":"125","author":"Jacinto","year":"2018","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.rmed.2026.108647_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/978-3-030-78771-4_36","article-title":"Exhaled nitric oxide (FeNO) in patients hospitalized for an exacerbation of bronchiectasis and\/or COPD: FeNO levels in COPD and bronchiectasis","volume":"1337","author":"Malli","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"8","key":"10.1016\/j.rmed.2026.108647_bib31","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/thoraxjnl-2018-212709","article-title":"Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study","volume":"74","author":"Busby","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2026.108647_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106156","article-title":"The effects of oral corticosteroids on lung function, type-2 biomarkers and patient-reported outcomes in stable asthma: a systematic review and meta-analysis","volume":"173","author":"Busby","year":"2020","journal-title":"Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2026.108647_bib41","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/resp.13026","article-title":"Co-morbidities in severe asthma: clinical impact and management","volume":"22","author":"Porsbjerg","year":"2017","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.rmed.2026.108647_bib29","doi-asserted-by":"crossref","DOI":"10.1080\/25310429.2024.2442662","article-title":"Fractional exhaled nitric oxide in a respiratory healthy general population through the lifespan","volume":"31","author":"Bal","year":"2025","journal-title":"Pulmonology"},{"issue":"9","key":"10.1016\/j.rmed.2026.108647_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.70107","article-title":"Reference values and determinants of fractional exhaled nitric oxide in a representative adult population in western Sweden","volume":"15","author":"Abohalaka","year":"2025","journal-title":"Clin. Transl. Allergy"},{"issue":"4","key":"10.1016\/j.rmed.2026.108647_bib33","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1164\/rccm.201806-1182OC","article-title":"Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma","volume":"199","author":"Heaney","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.rmed.2026.108647_bib38","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.chest.2022.10.014","article-title":"Developing fractional exhaled nitric oxide predicted and upper limit of normal values for a disadvantaged population","volume":"163","author":"Collaro","year":"2023","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.rmed.2026.108647_bib39","doi-asserted-by":"crossref","first-page":"992","DOI":"10.21037\/jtd.2016.03.72","article-title":"Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma","volume":"8","author":"Chen","year":"2016","journal-title":"J. Thorac. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2026.108647_bib40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.anai.2023.08.021","article-title":"Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry","volume":"132","author":"Scelo","year":"2024","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"26","key":"10.1016\/j.rmed.2026.108647_bib43","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.rmed.2026.108647_bib44","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/j.jaip.2022.06.036","article-title":"Dupilumab is effective in patients with moderate-to-severe uncontrolled GINA-defined type 2 asthma irrespective of an allergic asthma phenotype","volume":"10","author":"Rabe","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"3","key":"10.1016\/j.rmed.2026.108647_bib45","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","article-title":"Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial","volume":"13","author":"Castro","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2026.108647_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1121237","article-title":"Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps","volume":"14","author":"Pelaia","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2026.108647_bib47","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/02770903.2018.1545857","article-title":"Dupilumab in patients with uncontrolled asthma: type 2 biomarkers might be predictors of therapeutic efficacy","volume":"57","author":"Yang","year":"2020","journal-title":"J. Asthma"},{"issue":"9842","key":"10.1016\/j.rmed.2026.108647_bib48","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.rmed.2026.108647_bib49","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/cea.13613","article-title":"Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype","volume":"50","author":"Pelaia","year":"2020","journal-title":"Clin. Exp. Allergy"},{"issue":"8","key":"10.1016\/j.rmed.2026.108647_bib50","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1159\/000507996","article-title":"A comprehensive evaluation of mepolizumab effectiveness in a real-life setting","volume":"181","author":"Cameli","year":"2020","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"11","key":"10.1016\/j.rmed.2026.108647_bib51","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3390\/ph18111704","article-title":"Cytokine and metabolomic signatures of mepolizumab response across upper and lower airway compartments in severe eosinophilic asthma: an exploratory analysis","volume":"18","author":"Maniscalco","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.rmed.2026.108647_bib52","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1080\/02770903.2022.2136526","article-title":"Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma","volume":"60","author":"Menigoz","year":"2023","journal-title":"J. Asthma"},{"issue":"4","key":"10.1016\/j.rmed.2026.108647_bib53","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"issue":"suppl 64","key":"10.1016\/j.rmed.2026.108647_bib54","first-page":"2253","article-title":"Relationship between baseline fraction of exhaled nitric oxide (FeNO) and response to anti-IL-5\/5R therapies in severe eosinophilic asthma (SEA)","volume":"56","author":"Kavanagh","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"10423","key":"10.1016\/j.rmed.2026.108647_bib55","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.rmed.2026.108647_bib56","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1080\/02770903.2021.1963769","article-title":"Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients","volume":"59","author":"Watanabe","year":"2022","journal-title":"J. Asthma"},{"issue":"3","key":"10.1016\/j.rmed.2026.108647_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248305","article-title":"Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma","volume":"16","author":"Yamada","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2026.108647_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.107940","article-title":"The impact of blood eosinophil count and FeNO on benralizumab effectiveness in clinical practice: an ORBE II subanalysis","volume":"237","author":"Garc\u00eda-Moguel","year":"2025","journal-title":"Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2026.108647_bib59","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/all.16425","article-title":"Early reduction of FeNO on anti-IL5 biologics is associated with clinical remission of severe asthma","volume":"80","author":"Soendergaard","year":"2025","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.rmed.2026.108647_bib60","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1183\/23120541.00296-2024","article-title":"Revealing the gap: fractional exhaled nitric oxide and clinical responsiveness to biological therapy in severe asthma - a retrospective study","volume":"10","author":"Maniscalco","year":"2024","journal-title":"ERJ Open Res"},{"issue":"2","key":"10.1016\/j.rmed.2026.108647_bib61","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.rmed.2026.108647_bib62","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/biom13030538","article-title":"Pretreatment frequency of circulating Th17 cells and FeNO levels predicted the real-world response after 1 year of benralizumab treatment in patients with severe asthma","volume":"13","author":"Sandhu","year":"2023","journal-title":"Biomolecules"},{"issue":"19","key":"10.1016\/j.rmed.2026.108647_bib63","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.rmed.2026.108647_bib64","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.rmed.2026.108647_bib65","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/all.15197","article-title":"Baseline type 2 biomarker levels and response to tezepelumab in severe asthma","volume":"77","author":"Corren","year":"2022","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.rmed.2026.108647_bib66","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/all.16590","article-title":"Clinical and biological remission with tezepelumab: the real-world response in severe uncontrolled asthma","volume":"80","author":"Gates","year":"2025","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.rmed.2026.108647_bib67","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab severe uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2026.108647_bib68","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3390\/antiox12020400","article-title":"Exploring the Interaction between fractional exhaled nitric oxide and biologic treatment in severe asthma: a systematic review","volume":"12","author":"Pianigiani","year":"2023","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.rmed.2026.108647_bib69","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2026.108647_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113944","article-title":"Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma","volume":"179","author":"Frix","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.rmed.2026.108647_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13899","article-title":"Dupilumab: mechanism of action, clinical, and translational science","volume":"17","author":"McCann","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"4","key":"10.1016\/j.rmed.2026.108647_bib72","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.3390\/ijms26041729","article-title":"Eosinophil-driven vs. eosinophil-associated severe asthma: practical implications for target treatment","volume":"26","author":"D'Aiuto","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.rmed.2026.108647_bib73","first-page":"607","article-title":"Asthma biomarkers in sputum","volume":"27","author":"Spahn","year":"2007","journal-title":"Immunol. Allergy Clin."},{"key":"10.1016\/j.rmed.2026.108647_bib74","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.alit.2018.04.003","article-title":"Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthma","volume":"67S","author":"Soma","year":"2018","journal-title":"Allergol. Int."},{"issue":"5","key":"10.1016\/j.rmed.2026.108647_bib75","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/02770903.2015.1116086","article-title":"Clinical and inflammatory features of asthma with dissociation between fractional exhaled nitric oxide and eosinophils in induced sputum","volume":"53","author":"Crespo","year":"2016","journal-title":"J. Asthma"},{"issue":"13","key":"10.1016\/j.rmed.2026.108647_bib76","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.3390\/jcm14134749","article-title":"Biologic therapy in severe asthma: a phenotype-driven and targeted approach","volume":"14","author":"D'Amato","year":"2025","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.rmed.2026.108647_bib77","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2025.06.037","article-title":"Effect of dupilumab on small airways measured by airway oscillometry in VESTIGE","volume":"156","author":"Washko","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.rmed.2026.108647_bib82","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/thorax-2021-217865","article-title":"Randomised controlled trial for the titration of oral corticosteroids using markers of inflammation in severe asthma","volume":"78","author":"Ramsahai","year":"2023","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.rmed.2026.108647_bib84","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S2213-2600(25)00037-2","article-title":"Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials","volume":"13","author":"Meulmeester","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2026.108647_bib78","doi-asserted-by":"crossref","unstructured":"Rattu A, Dixey P, Charles D, et al. Predictors of response to biologics for severe asthma: a systematic review and meta-analysis. Allergy. Published online September 16, 2025. doi:10.1111\/all.70031.","DOI":"10.1111\/all.70031"},{"issue":"7","key":"10.1016\/j.rmed.2026.108647_bib79","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.jaip.2025.03.011","article-title":"Concurrent blood eosinophils and FeNO as biological therapy indicators in severe asthma: findings from the precision medicine Intervention in severe asthma study","volume":"13","author":"Pham","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"12","key":"10.1016\/j.rmed.2026.108647_bib80","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1080\/02770903.2024.2370012","article-title":"Evaluation of multiple-flows exhaled nitric oxide and its clinical significance in severe asthmatic patients treated with biologics: a prospective real-life study","volume":"61","author":"Pianigiani","year":"2024","journal-title":"J. Asthma"},{"issue":"11","key":"10.1016\/j.rmed.2026.108647_bib81","doi-asserted-by":"crossref","first-page":"9563","DOI":"10.3390\/ijms24119563","article-title":"Switching biological therapies in severe asthma","volume":"24","author":"Scioscia","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.rmed.2026.108647_bib83","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group","volume":"146","author":"Cloutier","year":"2020","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126000156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126000156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T03:18:45Z","timestamp":1771730325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126000156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":82,"alternative-id":["S0954611126000156"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108647","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fractional exhaled nitric oxide in monitoring biological treatment for severe asthma in adults: Clinical implications and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108647"}}